UroGen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $60.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 376.95% from the company’s previous close.
Other equities research analysts have also recently issued reports about the stock. Guggenheim assumed coverage on shares of UroGen Pharma in a research report on Thursday, August 22nd. They set a “buy” rating and a $40.00 price target on the stock. LADENBURG THALM/SH SH upped their target price on UroGen Pharma from $48.00 to $53.50 and gave the stock a “buy” rating in a report on Friday, June 14th. Finally, Oppenheimer raised their price target on UroGen Pharma from $32.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, June 14th.
Get Our Latest Research Report on URGN
UroGen Pharma Stock Up 0.8 %
UroGen Pharma (NASDAQ:URGN – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.09). The firm had revenue of $21.85 million for the quarter, compared to the consensus estimate of $23.69 million. On average, sell-side analysts expect that UroGen Pharma will post -3.49 EPS for the current fiscal year.
Institutional Investors Weigh In On UroGen Pharma
A number of institutional investors and hedge funds have recently modified their holdings of the company. Coastal Bridge Advisors LLC increased its position in UroGen Pharma by 4.1% during the second quarter. Coastal Bridge Advisors LLC now owns 38,500 shares of the company’s stock worth $646,000 after buying an additional 1,500 shares during the last quarter. Millennium Management LLC raised its stake in UroGen Pharma by 2,672.0% in the 2nd quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock valued at $19,480,000 after acquiring an additional 1,119,019 shares during the period. Point72 Asset Management L.P. lifted its holdings in UroGen Pharma by 120.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock valued at $41,099,000 after purchasing an additional 1,337,257 shares during the last quarter. Cubist Systematic Strategies LLC boosted its position in UroGen Pharma by 630.9% during the second quarter. Cubist Systematic Strategies LLC now owns 44,949 shares of the company’s stock worth $754,000 after purchasing an additional 38,799 shares during the period. Finally, Great Point Partners LLC boosted its position in UroGen Pharma by 10.9% during the second quarter. Great Point Partners LLC now owns 2,906,259 shares of the company’s stock worth $48,767,000 after purchasing an additional 285,714 shares during the period. 91.29% of the stock is owned by institutional investors.
About UroGen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
See Also
- Five stocks we like better than UroGen Pharma
- How to Find Undervalued Stocks
- SCHD ETF: Unlocking Passive Income With Strong Returns
- Compound Interest and Why It Matters When Investing
- NuScale Power Soars 270% – Analysts Forecasts More Gains Ahead
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Harness the Power of Dividend ETFs for Steady Income Growth
Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.